期刊文献+

Vasostatin基因重组腺病毒载体的构建及其对胰腺癌生长的抑制作用 被引量:4

Construction of replication-deficient recombinant adenovirus carrying vasostatin gene and its inhibitory effect on pancreatic cancer
下载PDF
导出
摘要 目的 以复制缺陷型腺病毒为载体 ,构建vasostatin基因重组腺病毒 ,并观察其对胰腺癌裸鼠移植瘤生长的抑制作用。方法 以人肌肉cDNA文库为模板应用PCR的方法扩增出vasostatin的DNA片断 ,定向插入腺病毒穿梭质粒 pshuttle CMV经酶切、测序鉴定正确后 ,电穿孔法将重组穿梭质粒转化E .coliBJ5 183 AdEasy 1感受态细菌 ,行细菌内同源重组。将抗性筛选和酶切鉴定正确的重组质粒 pAd CMV vasostatin转染 2 93细胞进行包装。病毒扩增纯化后 ,病毒感染人胰腺癌细胞 ,RT PCR和Western印迹法检测vasostatin的表达状况。复制人胰腺癌裸鼠移植瘤模型 ,瘤内注射 10 7pfupAd CMV vasostatin、10 8pfupAd CMV LacZ及PBS ,观察移植瘤的生长曲线及瘤重。 结果 PCR产物电泳后可见长度为 5 6 0bp左右的目的条带 ;酶切及测序鉴定表明穿梭质粒 pshuttle CMV中插入了vasostatin的DNA片断 ;卡那霉素抗性筛选及PacI酶切鉴定证实腺病毒重组质粒 pAd CMV vasostatin构建成功 ;转染 2 93细胞 7天后观察到细胞病理学效应出现。PCR鉴定表明重组腺病毒中含有vasostatin片断。RT PCR和Western印迹法证实vasostatinmRNA及蛋白的表达。治疗后 3周 pAd CMV vasostatin组移植瘤的体积及瘤重均显著小于 pAd CMV LacZ组及PBS组。 Objective To construct the replication-deficient recombinant adenovirus carrying vasostatin gene and study its inhibitory effect on pancreatic cancer. Methods A cDNA clone encoding vasostatin was isolated from human skeletal muscle cDNA library by polymerase chain reaction. The shuttle plasmid, pshuttle-CMV-vasostatin, in which the amplified fragment was inserted into the downstream of the cytomegalovirus promoter, was established by ligation. After identification by digestion and sequencing, linearize the shuttle plasmid with Pme I, and then transform the linearized shuttle plasmid into E.coli BJ5183-AdEasy-1 by electroporation. The plasmid was named as pAd-CMV-vasostatin after homologous recombination and identification by kanamycin-selection and restriction digestion. The recombinant plasmid was transfected into cell 293. The recombinant adenovirus was detected by examining the presence of cytopathic effect and identified by polymerase chain reaction. Both RT-PCR and western blotting were used to identify the expression of vasostatin. The xenografted nude mice with pancreatic cancer were established to observe the inhibitory effect of vasostatin on tumor growth. The volume of xenografts was measured every three days during the 3-week treatment. The weight of xenografts was measured at the end of the 21st day. Results The PCR product was about 560 bp confirmed by agarose gel electrophoresis. The successful cloning of vasostatin into pshuttle-CMV was confirmed by restriction endonuclease analysis, and the gene of interest was identified as vasostatin by nucleotides sequencing technique. The recombinants were selected for kanamycin resistance and the recombination was confirmed by the presence of 4.5kb fragment in the restriction endonuclease analysis. The cytopathic effect present after 7 days in cell 293 transfected with linearized pAd-CMV-vasostatin. Both the cytopathic effect of cell 293 and the 560 bp PCR producet indicated the presence of the recombinant adenovirus containing vasostatin gene. The expression of vasostatin was identified by RT-PCR and western blotting. The volume and weight of xenografts in pAd-CMV-vasostatin group were significantly smaller than those in pAd-CMV-LacZ group and PBS group. Conclusion The recombinant adenovirus containing vasostatin gene was constructed successfully, and could significantly inhibit the growth of xenografted pancreatic cancer in nude mice.
出处 《肿瘤》 CAS CSCD 北大核心 2004年第6期538-541,共4页 Tumor
关键词 Vasostatin基因 基因治疗 遗传载体 胰腺肿瘤 异种移植模型抗肿瘤试验 小鼠 Vasostatin gene Gene therapy Genetic vectors Pancreatic neoplasms Xenograft model antitumor assay Mice,nude
  • 相关文献

参考文献8

  • 1McCauliffe DP, Lux FA, Lieu TS, et al. Molecular cloning,expression, and chromosome 19 localization of a human Ro/SS-A autoantigen[J]. J Clin Invest, 1990,85 : 1379
  • 2Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth[J]. J Exp Med, 1998,188: 2349
  • 3Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin[J]. Gene Ther, 2002,9:1207
  • 4Yao L, Pike SE, Setsuda J, et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12[J]. Blood, 2000,96: 1900
  • 5Francis PJ, Stout JT. Gene therapy and control of angiogenesis[J]. Ophthalmol Clin North Am , 2003, 16:575
  • 6St George JA. Gene therapy progress and prospects: adenoviral vectors[J]. Gene Ther, 2003, 10: 1135-1141.
  • 7He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses[J]. Proc Natl Acad Sci U S A ,1998, 95:2509
  • 8Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth[J]. Blood, 1999, 94:2461

同被引文献46

  • 1李雷,袁耀宗,章永平,乔敏敏,卢健.Vasostatin基因对胰腺癌血管生成的抑制作用[J].中华消化杂志,2005,25(10):590-593. 被引量:4
  • 2李雷,袁耀宗,章永平,乔敏敏,卢健.Vasostatin基因对胰腺癌细胞和血管内皮细胞增殖的影响[J].胰腺病学,2006,6(1):12-15. 被引量:2
  • 3李雷,袁耀宗,章永平,乔敏敏,卢健.腺病毒介导的Vasostatin基因对血管内皮细胞的作用[J].上海交通大学学报(医学版),2006,26(5):511-515. 被引量:1
  • 4Pike SE,Yao L,Jones KD,et al.Vasostatin,a calreticulin fragment,inhibits angiogenesis and suppresses tumor growth.J Exp Med,1998,188:2349-2356.
  • 5Matsubara K,Matsumoto H,Mizushina Y,et al.Inhibitory effect of pyridoxal 5′-phosphate on endothelial cell proliferation,replicative DNA polymerase and DNA topoisomerase.Int J Mol Med,2003,12:51-55.
  • 6Folkman J.Fundamental concepts of the angiogenic process.Curr Mol Med,2003,3:643-651.
  • 7Francis PJ,Stout JT.Gene therapy and control of angiogenesis.Ophthalmol Clin North Am,2003,16:575-582.
  • 8Xiao F,Wei Y,Yang L,et al.A gene therapy for cancer based on the angiogenesis inhibitor,vasostatin.Gene Ther,2002,9:1207-1213.
  • 9Taraboletti G,Giavazzi R.Modelling approaches for angio-genesis.Eur J Cancer,2004,40:881-889.
  • 10Yeo CJ. Pancreatic cancer: 1998 update. J Am Coll Surg, 1998,187:429-442.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部